China SXT Pharmaceuticals, Inc. (SXTC)

CN — Healthcare Sector
Peers: ATLN  TNXP  IXHL  CYBN  AVR  SAVA  FATE  IPHA  MIST  NVCT 

Automate Your Wheel Strategy on SXTC

With Tiblio's Option Bot, you can configure your own wheel strategy including SXTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SXTC
  • Rev/Share 0.5429
  • Book/Share 8.2833
  • PB 0.0052
  • Debt/Equity 0.0595
  • CurrentRatio 4.3684
  • ROIC -0.1102

 

  • MktCap 5517964.0
  • FreeCF/Share -0.6832
  • PFCF -3.3066
  • PE -0.0363
  • Debt/Assets 0.0457
  • DivYield 0
  • ROE -0.1755

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
SXTC
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral

TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to the purchase price for each Share, less the exercise price of $0.001 per share.

Read More
image for news China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
SXTC
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session …

Read More
image for news China SXT Pharmaceuticals, Inc. Announces Share Consolidation

About China SXT Pharmaceuticals, Inc. (SXTC)

  • IPO Date 2019-01-04
  • Website https://www.sxtchina.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Feng Zhou
  • Employees 75
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.